Back to test list


Test category:

Oncology - Lymphoma

Use of test


​Gene fusions involving the IGH/IGK/IGL genes and CCND2 at 12p13 are seen most frequently in mantle cell lymphoma, this being a variant of the rearrangements involving CCND1. The identification of such fusions can assist in diagnosis and classification of disease.


​Presence of an IGH/IGK/IGL-CCND2 gene fusion can be useful in diagnosing mantle cell lymphoma.

Ethical considerations:

This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.


Fluorescent in situ hybridisation (FISH) analysis of the CCND2 gene. The breakpoints involved in these fusions can be variable, and in some cases certain variants will not be detected by the probe.

Requesting the test


This test is usually requested by an oncologist.

Sample required:

​0.5 mL bone marrow in transport media, or formalin-fixed, paraffin embedded tissue (FFPE).

Special instructions:

To help ensure the quality of the test, a genetic test should be done with a dedicated sample whenever possible i.e. a sample collected specifically for that test rather than a sample that is used for multiple tests.

We recommend that the patient or another adult check the labelling of request forms and sample tubes.

Turnaround time:

5 business days.


Up to $255.

If more information is required, the requesting clinician can call our laboratory on (07) 3377 8573.


This test is not rebated by Medicare. The laboratory assumes that the patient or client has provided informed financial consent for the test.

Click here for our billing policy.